Arbor Biotechnologies

Company Snapshot

Founded: 2016
Entity Type: Private
Region: U.S.
Headquarter: Massachusetts, U.S.
Key Geographics: North America
Corporate Address: 20 Acorn Park Drive, Suite 500 Cambridge, Massachusetts 02140 U.S. Tel. NA www.arbor.bio

Company Overview

Arbor Biotechnologies is an early-stage life sciences company based in Cambridge, Mass. Arbor was founded to curate genetic biodiversity and discover novel protein functions from nature by integrating proprietary high-throughput platforms with computational biology tools. Leveraging its innovative discovery platform, Arbor aims to transform the discovery of proteins to improve human health and sustainability.

Arbor’s discovery platform employs various technologies and techniques, including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, to curate and mine the natural genetic diversity for impactful peptides, proteins, and enzymes, enabling systematic and high-throughput discovery of new molecules.

Arbor was founded in 2016 by Feng Zhang of the Broad Institute at MIT, David Walt of the Wyss Institute at Harvard, and other founders. In June 2017, the company closed its $15.6 million Series A financing, led by Keith Crandell of ARCH Venture Partners, Annie Hazlehurst of Faridan Ventures and several private investors.

Utilizing its platform in March 2018, Arbor Biotechnologies published its first findings of a new member of the CRISPR-Cas13 enzyme family—Cas13d. The new enzyme is much smaller than other members of the CRISPR-Cas13 family and has implications for RNA manipulation and highly sensitive diagnostics applications.

Arbor Biotechnologies In Reports

Genome Editing: Technologies and Global Markets

Global genome editing market should reach $12.8 billion by 2027 from $4.3 billion in 2022 at a CAGR of 24.7% for the forecast period of 2022-27.

Synthetic Biology: Global Markets

BCC Research Market Report for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 billion by 2026, at a compound annual growth rate of 28.4%

Synthetic Biology: Global Markets

The global synthetic biology market should grow from $5.3 billion in 2019 to $18.9 billion by 2024 with a compound annual growth rate (CAGR) of 28.8% for the period of 2019-2024.

Company's Business Segments

  • Genetic Medicines : This segment focused on Discovering, Developing Potentially Curative Genomic Medicines.

Applications/End User Industries

  • Biotechnology
  • Bioengineering
  • Discovery Science
  • Molecular Biology
  • DNA Sequencing
  • Machine Learning
  • DNA Synthesis
  • Protein Biology
  • CRISPR
  • Gene Editing
  • Life Sciences
AI Sentiment